Stockscreener 앱 받기
17.04
0.23%
0.12
전일 마감가:
$16.92
열려 있는:
$17
하루 거래량:
29,762
Relative Volume:
0.15
시가총액:
$580.62M
수익:
$99.99M
순이익/손실:
$-21.47M
주가수익비율:
-25.83
EPS:
-0.6597
순현금흐름:
$-11.34M
1주 성능:
+6.99%
1개월 성능:
+0.94%
6개월 성능:
+2.78%
1년 성능:
-4.08%
1일 변동 폭
$16.75
$17.40
1주일 범위
$15.62
$17.40
52주 변동 폭
$7.5625
$19.60
뉴로페이스 Stock (NPCE) Company Profile
명칭
Neuropace Inc
전화
(650) 237-2700
주소
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Compare NPCE vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
17.03 | 576.87M | 99.99M | -21.47M | -11.34M | -0.6597 |
ABT
Abbott Laboratories
|
86.53 | 152.25B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
312.00 | 121.33B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.09 | 100.91B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.97 | 85.88B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.12 | 49.39B | 6.30B | 1.07B | 1.09B | 1.8406 |
뉴로페이스 Stock (NPCE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-28 | 개시 | H.C. Wainwright | Buy |
| 2025-01-21 | 개시 | UBS | Buy |
| 2024-03-14 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | 개시 | Leerink Partners | Outperform |
| 2023-11-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-08-24 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | 개시 | Lake Street | Buy |
| 2022-04-06 | 개시 | Wolfe Research | Outperform |
| 2022-01-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | 개시 | Robert W. Baird | Outperform |
| 2021-05-17 | 개시 | JP Morgan | Overweight |
| 2021-05-17 | 개시 | Morgan Stanley | Overweight |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-17 | 개시 | Wells Fargo | Overweight |
모두보기
뉴로페이스 주식(NPCE)의 최신 뉴스
(NPCE) Risk Channels and Responsive Allocation - Stock Traders Daily
NeuroPace (NPCE) Q1 2026 Earnings Transcript - AOL.com
NeuroPace (NPCE) up 0.9% since last earnings report: Can it continue? - MSN
NeuroPace (NPCE) CFO receives RSU and stock option awards in Form 4 filing - Stock Titan
NeuroPace (NPCE) CMO receives new RSU and stock option awards - Stock Titan
NeuroPace (NPCE) CEO receives new RSU and stock option awards - Stock Titan
Here's why you should add NeuroPace stock to your portfolio now - MSN
H.C. Wainwright raises NeuroPace stock price target to $20 on guidance - Investing.com Australia
NPCE Maintains by HC Wainwright & Co. -- Price Target Raised to $20 - GuruFocus
First Light, Mathew Arens report ~2.9M NPCE shares (NPCE) - Stock Titan
OrbiMed reports 2,096,527 shares (6.2%) in NeuroPace (NPCE) - Stock Titan
H.C. Wainwright Maintains NeuroPace(NPCE.US) With Buy Rating, Raises Target Price to $20 - Moomoo
Wells Fargo Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $19 - Moomoo
NeuroPace, Inc. (NASDAQ:NPCE) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - simplywall.st
(NPCE) Movement as an Input in Quant Signal Sets - Stock Traders Daily
NeuroPace, Inc. (NASDAQ:NPCE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
NeuroPace, Inc. (NPCE) reports Q1 loss, tops revenue estimates - MSN
Should You Investigate NeuroPace, Inc. (NASDAQ:NPCE) At US$15.81? - Moomoo
Neuropace Warns Cybersecurity Threats to Intracranial EEG Data Could Hit Operations, Reputation and Growth - TipRanks
Lake Street Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $20 - Moomoo
NeuroPace Earnings Call Highlights RNS Growth Momentum - TipRanks
Neuropace signals $99M-$101M 2026 revenue outlook while targeting 21%-23% underlying RNS growth - MSN
NPCE Stock Gains on Q1 Earnings & Revenue Beat, 2026 Outlook Raised - TradingView
NeuroPace, Inc. (NASDAQ:NPCE) Q1 2026 Earnings Call Transcript - Insider Monkey
NeuroPace revenue up 20.1% to USD 22.1M in Q1 2026 - Medical Buyer
NeuroPace, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
NeuroPace Q1 Loss Narrows, Revenue Declines - Moomoo
NeuroPace (NPCE) Q1 Loss Near US$6.7 Million Tests Bullish Profitability Narratives - Sahm
NeuroPace Q1 2026 Earnings Call Transcript - MarketBeat
Earnings Call Summary | NeuroPace(NPCE.US) Q1 2026 Earnings Conference - Moomoo
NeuroPace Non-GAAP Operating Expenses Outlook Excludes Approximately $10M in Stk-based Compensation, a Non-Cash Expense >NPCE - Moomoo
NeuroPace Q1 Earnings Call Highlights - MarketBeat
NeuroPace Inc revenue rises to 22.1 million as RNS System delivers 20 percent YoY growth - Traders Union
NeuroPace : Investor Presentation - marketscreener.com
Earnings call transcript: NeuroPace Q1 2026 shows revenue growth, stock stable - Investing.com Nigeria
Earnings call transcript: NeuroPace Q1 2026 shows revenue growth, stock stable By Investing.com - Investing.com South Africa
NeuroPace, Inc. (NPCE) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
NeuroPace Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
[10-Q] NeuroPace Inc Quarterly Earnings Report - Stock Titan
NeuroPace (NASDAQ:NPCE) Beats Q1 Estimates, Raises Full-Year Revenue Guidance - ChartMill
NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance - Investing News Network
NeuroPace Inc.: Q1 Earnings Snapshot - marketscreener.com
NeuroPace Q1 revenue rises 20%, beats estimates, raises 2026 outlook - TradingView
NeuroPace beats Q1 estimates, raises full year revenue guidance - Investing.com UK
NeuroPace beats Q1 estimates, raises full year revenue guidance By Investing.com - Investing.com Australia
뉴로페이스 (NPCE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.32%
0.17%
자본화:
|
볼륨(24시간):